Want to see NEXI full AI Analyst Report?
NEXI Stock Chart & Stats
$2.17
$0.01(10.71%)
At close: 4:00 PM EST
$2.17
$0.01(10.71%)
Day’s Range― - ―
52-Week Range$0.00 - $2.17
Previous CloseN/A
Volume4.35K
Average Volume (3M)62.00
Market Cap
$139.00
Enterprise Value$1.37
Total Cash (Recent Filing)$2.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2614.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,394,671
10 Day Avg. Volume45
30 Day Avg. Volume62
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary TechnologyNexImmune's AIM technology offers a unique approach to immunotherapy, potentially differentiating it in the competitive biotech space.
Partnership OpportunitiesCollaborations with larger pharmaceutical companies can provide capital and resources, aiding in product development and market entry.
Low LeverageA low leverage position provides financial flexibility and reduces risk, allowing NexImmune to potentially withstand financial challenges better.
Bears Say
Lack Of RevenueThe absence of revenue indicates challenges in commercializing products, which could hinder long-term financial sustainability and growth.
Consistent LossesOngoing losses suggest operational inefficiencies and the need for strategic adjustments to achieve profitability and sustain operations.
Negative Cash FlowNegative cash flow challenges liquidity and sustainability, necessitating improved cash management or external funding to maintain operations.
NexImmune News
NEXI FAQ
What was NexImmune’s price range in the past 12 months?
NexImmune lowest stock price was $0.00 and its highest was $2.17 in the past 12 months.
What is NexImmune’s market cap?
NexImmune’s market cap is $139.00.
When is NexImmune’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NexImmune’s earnings last quarter?
Currently, no data Available
Is NexImmune overvalued?
According to Wall Street analysts NexImmune’s price is currently Overvalued.
Does NexImmune pay dividends?
NexImmune does not currently pay dividends.
What is NexImmune’s EPS estimate?
NexImmune’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NexImmune have?
NexImmune has 1,394,671 shares outstanding.
What happened to NexImmune’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NexImmune?
Currently, no hedge funds are holding shares in NEXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NexImmune
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
NEXI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
―
Insiders
0.36% Mutual Funds
7.35% Other Institutional Investors
92.29% Public Companies and
Individual Investors